Asklepios BioPharmaceutical: Funding, Investors & Team (Sep 2026)
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Asklepios BioPharmaceutical has raised $2.0M across 1 funding round on record, the most recent an undisclosed round of $2.0M announced in Sep 2020.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Asklepios BioPharmaceutical Company Profile and Key Stats
Latest funding round on record: Sep 2020.
Asklepios BioPharmaceutical Funding Rounds
Asklepios BioPharmaceutical Founders and Leadership Team
Contact details for the Asklepios BioPharmaceutical team: 1 of 1 has an email address on file.
Start 14-day free trial →Asklepios BioPharmaceutical Funding Compared to Other Biotechnology Startups
Asklepios BioPharmaceutical's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Asklepios BioPharmaceutical in Biotechnology and Chapel Hill
Companies Similar to Asklepios BioPharmaceutical
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Asklepios BioPharmaceutical Funding FAQs
What does Asklepios BioPharmaceutical do?
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
How much funding has Asklepios BioPharmaceutical raised?
Asklepios BioPharmaceutical has raised $2.0M across 1 round on record. The most recent is an undisclosed round of $2.0M announced in Sep 2020.
When did Asklepios BioPharmaceutical last raise funding?
Asklepios BioPharmaceutical's most recent funding round on record is an undisclosed round of $2.0M, announced in Sep 2020.
Who is the CEO of Asklepios BioPharmaceutical?
Sheila Mikhail is listed as CEO at Asklepios BioPharmaceutical.
Where is Asklepios BioPharmaceutical headquartered?
Asklepios BioPharmaceutical is based in Chapel Hill, North Carolina, United States.
How many employees does Asklepios BioPharmaceutical have?
Asklepios BioPharmaceutical is in the 101-250 employee band.
How does Asklepios BioPharmaceutical's funding compare to other Biotechnology startups?
Asklepios BioPharmaceutical's latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Asklepios BioPharmaceutical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Asklepios BioPharmaceutical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.